Agenus to Present at the Jefferies 2016 Healthcare Conference

LEXINGTON, Mass.–(BUSINESS WIRE)– Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing
antibodies including checkpoint inhibitors and other checkpoint
modulators, and cancer vaccines, today announced that Garo H. Armen,
Ph.D., Chairman and CEO, and Robert B. Stein, M.D., Ph.D., President,
Research & Development, will present a corporate overview at the
Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9^th
at 9:30am ET.

Webcast Information

The live and archived webcast of the presentation will be accessible
from the Company’s website at www.agenusbio.com/webcast.
Please log in approximately 5-10 minutes before the event to ensure a
timely connection. The archived replay will be available on the Agenus
website for one month following the conference.

About Agenus

Agenus is an immuno-oncology company focused on the discovery and
development of revolutionary new treatments that engage the body’s
immune system to benefit patients suffering from cancer. By combining
multiple powerful platforms, Agenus has established a highly integrated
approach for the discovery, development and manufacture of monoclonal
antibodies that modulate targets of interest. In addition, the Company’s
cancer vaccine program includes three proprietary platforms focused on
individualized and off-the-shelf vaccines uniquely designed for each
patient. Agenus’ broad portfolio of novel checkpoint and other
immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in
combination to provide the opportunity to create best-in-class
therapeutic regimens. The Company has formed collaborations with Merck
and Incyte to discover and develop multiple checkpoint antibodies. For
more information, please visit www.agenusbio.com;
information that may be important to investors will be routinely posted
on our website.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160602005140/en/